I-MAK has also made false and misleading claims about the number of patents that cover brand name drugs. Amgen Addresses the CriticsAgainst the backdrop of charlatans with hollow rationales and contrived grievances, Amgen has recently jumped into the ongoing public policy debates about biologic manufacturing patents and whether such patents unfairly delay the entry of biosimilars—a similar yet still bogus refrain. With the biosimilar’s manufacturing process in mind, a skilled patent searcher could easily sift through the innovator’s patents and find relevant manufacturing patents within a matter of days.”Amgen also emphasizes that manufacturing-related patents protect valuable process technology. Such patents are new composition of matter patents, not technically follow-on patents, that generate a new patent term of protection for the improved product. Biologic manufacturing patents protecting these innovations are not invalid for prior use, nor is there a sea of FDA submissions containing evidence of prior use.